Purpose: To evaluate the efficacy of fluoxetine alone and fluoxetine + lidocaine ointment in the same patient group with premature ejaculation (PE). Material and Methods: 78 patients with PE were given 20 mg fluoxetine by an ‘as-needed treatment’ 4 h before planned sexual activity for a period of 3 months. They were then told to add local lidocaine ointment to fluoxetine 30 min before sexual activity for an additional 3 months for most of their sexual attempts. They were asked to note their PE grades and intravaginal ejaculatory latency time (IELT) scores by stopwatch technique before and after each treatment modality; the results were compared statistically afterwards. Results: Of 46 patients who completed the study, the mean pretreatment, fluoxetine alone and fluoxetine + lidocaine ointment treatment PE grades and IELT scores were found to be 6.52 ± 1.42 and 2.58 ± 0.49, 3.21 ± 1.86 and 1.28 ± 0.71, 2.17 ± 1.56 and 1.04 ± 0.72, respectively, showing a decrease in PE grades and IELT scores in combined therapy. On an individual patient basis, the total significant and moderate improvement rate of combined therapy was found to be 86.9%. Failure was observed in 6 (13.1%) patients. Conclusion: The effective treatment with fluoxetine + lidocaine ointment offers the advantage of an ‘as-needed treatment’ in PE with minimal side effects and can be used as one of the first-line alternatives in the treatment of PE.

Keywords:
Premature ejaculation, Fluoxetine, Lidocaine
This content is only available via PDF.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.